Biotech entity
Bundibugyo virus is the most frequent co-covered peer, appearing in 2 of the 3 tracked stories. The clearest coverage concentration is clinical-trial: 2 of 3 stories, with the rest divided among 1 other category. Each story carries 2 original sources on average, compared with 3.6 for the broader beat in this window.
Last mentioned: Jun 15, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 33 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Bundibugyo virus is the most frequent co-covered peer, appearing in 2 of the 3 tracked stories. The clearest coverage concentration is clinical-trial: 2 of 3 stories, with the rest divided among 1 other category. Each story carries 2 original sources on average, compared with 3.6 for the broader beat in this window. That works out to roughly 0.2 stories per week across a 129-day span. Their average consequence score of 7 runs above the beat's 6.2 for that window. We currently track 3 Biotech stories that mention Africa Centres for Disease Control and Prevention, published between March 5, 2026 and July 11, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 380 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Africa Centres for Disease Control and Prevention. Shared-story counts are live from our verified record — not editorial picks.
US aid worker tests positive
CDC confirms a US citizen aid worker in Congo has Ebola; contact tracing and containment measures initiated.
Record outbreak confirmed
Africa CDC reports 1,830 confirmed cases and 648 deaths, marking the fastest-growing Ebola outbreak ever recorded on the continent.
Clinical trials for Ebola treatment begin
Researchers launch a highly anticipated study to test experimental therapies against the Bundibugyo strain.
Kenya Ebola facility suspended
A Kenyan court orders suspension of construction on a US-backed isolation facility for exposed Americans, pausing Trump administration plans.
First US doctor infected
An American doctor working in Congo tests positive during outbreak's first week and is transferred to Germany for treatment.
Congo declares fresh Ebola outbreak
Authorities announce outbreak of Bundibugyo virus after weeks of undetected transmission, according to WHO.
The Congo Ebola outbreak driven by the rare Bundibugyo virus has ballooned to 1,830 cases with zero approved vaccines or treatments, forcing an urgent launch of clinical trials. For biotech and pharma, this emergency opens a race to develop broad-spectrum filovirus countermeasures.
The rare Bundibugyo Ebola virus has infected 782 people and killed 181 in Congo, with a record 72 new cases in one day. No approved vaccine or treatment exists for this strain, creating an urgent gap for biotech and pharma to address with rapid countermeasure development.
At the Roche Africa Press Day, health leaders and the Africa CDC called for a fundamental shift in laboratory financing, moving from reactive emergency response to permanent national infrastructure. The transition is tied to the upcoming 2026 global pandemic agreement, which aims to mandate pathogen data sharing in exchange for equitable access to medical countermeasures.
Africa Centres for Disease Control and Prevention is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
